351 related articles for article (PubMed ID: 19482958)
1. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C; Maione P; Ferrara ML; Rossi A
Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
[TBL] [Abstract][Full Text] [Related]
2. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
4. EGFR-directed monoclonal antibodies in non-small cell lung cancer.
Pirker R
Target Oncol; 2013 Mar; 8(1):47-53. PubMed ID: 23300028
[TBL] [Abstract][Full Text] [Related]
5. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Pirker R; Minar W; Filipits M
Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
[TBL] [Abstract][Full Text] [Related]
6. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
Joy AA; Butts CA
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.
Socinski MA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4597-601. PubMed ID: 17671148
[TBL] [Abstract][Full Text] [Related]
8. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Kim ES
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in non-small cell lung cancer.
Ademuyiwa FO; Hanna N
Expert Opin Biol Ther; 2008 Jan; 8(1):107-13. PubMed ID: 18081540
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Kollmannsberger C; Schittenhelm M; Honecker F; Tillner J; Weber D; Oechsle K; Kanz L; Bokemeyer C
Ann Oncol; 2006 Jun; 17(6):1007-13. PubMed ID: 16533873
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies against EGFR in non-small cell lung cancer.
Pirker R; Filipits M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
[TBL] [Abstract][Full Text] [Related]
15. EGFR pathway in advanced non-small cell lung cancer.
Merlo V; Longo M; Novello S; Scagliotti GV
Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
[TBL] [Abstract][Full Text] [Related]
16. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment.
Capdevila J; Elez E; Macarulla T; Ramos FJ; Ruiz-Echarri M; Tabernero J
Cancer Treat Rev; 2009 Jun; 35(4):354-63. PubMed ID: 19269105
[TBL] [Abstract][Full Text] [Related]
17. New insights in drug development for the non-small cell lung cancer therapy.
Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab in advanced non-small cell lung cancer.
Rossi A; Maione P; Gridelli C
Crit Rev Oncol Hematol; 2006 Aug; 59(2):139-49. PubMed ID: 16806963
[TBL] [Abstract][Full Text] [Related]
19. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
20. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
Takeda M; Nakagawa K
Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
